~~<i id='542F1FD5FC'><strike id='542F1FD5FC'><tt id='542F1FD5FC'><pre id='542F1FD5FC'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

hotspot

author：focus 2025-10-01 17:09:46 - browse：532

A man, who is suffering from frostbite, displays his hands. -- health coverage from STAT — Jon Cherry/Getty Images

Two days after his right hand froze, Hart Bezner realized for the first time that he might lose it.

The retired physics professor was sitting in an emergency room in Whitehorse, the capital of Canada’s Yukon territory, where two doctors and a pharmacist were taking an unusual amount of interest in the appendage and the pink blisters that now covered it.

“Will I lose my hand?” he remembers asking. “Will this go away?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Biden report: The neurospychology of memory and aging

focus

entertainment

hotspot

focus

leisure time

explore

AdobeThreebiotechVCveterans,includingoneoftheco-foundersofradiopharmasuccessstoryRayzeBio,arelaunchi

WSS

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Poor hospice wound care hurts patients and families

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

David Sabatini, ex

PBM reforms clear House panel

Medicare Advantage proposed rates disappoint insurers

explore

hotspot

focus

Apple is now the first public company to be valued at $3 trillion

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Medicare threatens to cut off funding for HCA's Mission hospital

Virginia high school admissions case could be legal follow

Why did Pfizer dish out millions for a Super Bowl ad?

Psychedelics group wrestles with new pharma identity

What we’ve learned from the Aduhelm mess

Medicare details structure of new drug price negotiation program

What should King Charles tell the public about his cancer?

entertainment

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Congress must reauthorize a committee to support older Americans

World's first CRISPR

Weight loss drug costs may need more research, senator suggests

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

hotspot

focus

leisure time

explore